SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Yan Pei)
 

Sökning: WFRF:(Yan Pei) > Dynamic toxicity la...

  • Liu, LihuiChinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China.;Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, State Key Lab Mol Oncol,Canc Hosp, Beijing, Peoples R China. (författare)

Dynamic toxicity landscape of immunotherapy for solid tumors across treatment lines

  • Artikel/kapitelEngelska2023

Förlag, utgivningsår, omfång ...

  • Elsevier,2023
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-518348
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-518348URI
  • https://doi.org/10.1016/j.jncc.2023.07.002DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Objective: Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1/ligand-1 (PD-1/PD-L1), cytotoxic T lymphocyte antigen-4 (CTLA-4), and lymphocyte-activation gene-3 (LAG-3) have been widely studied and applied throughout the course of cancer treatment. This study aimed to provide a comprehensive profile of ICI-associated toxicity and elucidate the toxicity patterns of ICIs across different treatment lines. Methods: In total, 155 cohorts comprising 24 539 eligible patients were included in the safety analysis. Trial name, registration number, cancer type, trial phase, clinical setting, trial design, regimen, dosing schedule, age, sex and ethnicity distributions, number of patients, number of treatment-related adverse events (trAEs), and number of treatment-related death were extracted. We defined a timeline from the neoadjuvant setting to the third-line setting. We also introduced a synthesizing principle for adverse event rates (SPAER) of immunotherapy to ensure the comparability and reliability across different treatment lines. The study protocol was registered and approved by the PROSPERO protocol review committee (CRD42021242368). Results: After excluding the neoadjuvant setting group, we observed a distinct reduction in the incidence of treatment-related adverse events (trAEs) with an advancement of the line of ICI treatment. The incidence of trAEs was negatively correlated with the line of treatment, irrespective of whether monotherapy or dual-ICI combination therapy was administered. Sensitivity analyses also confirmed the coincident negative correlations. Conclusion: In summary, using a timeline-based concept centered around treatment lines, we revealed the dynamic landscape of ICI-associated toxicity and found that patients treated with ICIs during later lines of therapy may have a lower risk of trAEs.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Li, SiniChinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China.;Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, State Key Lab Mol Oncol,Canc Hosp, Beijing, Peoples R China. (författare)
  • Wang, GuoqiangBurning Rock Biotech, Guangzhou, Peoples R China. (författare)
  • Qu, YanChinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China.;Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, State Key Lab Mol Oncol,Canc Hosp, Beijing, Peoples R China. (författare)
  • Wang, ZhijieChinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China.;Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, State Key Lab Mol Oncol,Canc Hosp, Beijing, Peoples R China. (författare)
  • Duan, JianchunChinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China.;Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, State Key Lab Mol Oncol,Canc Hosp, Beijing, Peoples R China. (författare)
  • Wang, ChaoChinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China.;Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, State Key Lab Mol Oncol,Canc Hosp, Beijing, Peoples R China. (författare)
  • Xue, PeiUppsala universitet,Institutionen för kirurgiska vetenskaper(Swepub:uu)peixu326 (författare)
  • Zhang, XueChinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China.;Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, State Key Lab Mol Oncol,Canc Hosp, Beijing, Peoples R China. (författare)
  • Ma, ZixiaoChinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China. (författare)
  • Bai, HuaChinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China.;Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, State Key Lab Mol Oncol,Canc Hosp, Beijing, Peoples R China. (författare)
  • Wang, JieChinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China.;Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, State Key Lab Mol Oncol,Canc Hosp, Beijing, Peoples R China. (författare)
  • Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China.;Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, State Key Lab Mol Oncol,Canc Hosp, Beijing, Peoples R China.Burning Rock Biotech, Guangzhou, Peoples R China. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of the National Cancer Center: Elsevier3:3, s. 186-1962667-0054

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy